Odyral (Dorzolamide)

Dorzolamide inhibits carbonic anhydrase in the ciliary body, decreasing the production of aqueous humor. This reduction in fluid formation lowers intra‑ocular pressure, which helps to protect the optic nerve from pressure‑related damage in glaucoma and ocular hypertension.

The dosing schedule for Odyral is determined by the prescribing ophthalmologist based on the patient’s condition, severity, and response to therapy. Typically, one drop is instilled in the affected eye(s) one to three times daily, but the exact regimen must be individualized.

Safety data for dorzolamide in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To request Odyral, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Odyral (dorzolamide) belongs to the carbonic anhydrase inhibitor class, which lowers intra‑ocular pressure by reducing aqueous humor production. This mechanism differs from beta‑blockers that decrease fluid production via adrenergic blockade, and from prostaglandin analogues that increase outflow. Choice of therapy depends on efficacy, tolerability, patient comorbidities and physician preference.

Store Odyral eye drops at room temperature, below 25 °C, in the original container. Keep the bottle tightly closed, protect it from light and moisture, and do not freeze. Do not use the product after the expiration date printed on the label.

Odyral is applied as a sterile ophthalmic solution. The patient should wash hands, tilt the head back, pull down the lower eyelid, and place a single drop into the conjunctival sac of the affected eye(s). Close the eye gently and avoid blinking excessively for a few seconds to allow absorption.

Although uncommon, serious adverse reactions can include severe allergic responses such as angioedema or Stevens‑Johnson syndrome, persistent ocular pain, and sudden loss of vision. Patients should seek immediate medical attention if they experience swelling of the eyelids, rash, or any rapid deterioration in visual acuity.

Odyral is contraindicated in individuals with known hypersensitivity to dorzolamide, any carbonic anhydrase inhibitor, or any component of the formulation. It should also be avoided in patients with severe sulfonamide allergy, as cross‑reactivity may occur. Consultation with an eye care professional is essential before initiating therapy.